Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B4a7c256fe8e82ce3a90b0dbaafc6581c> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B4a7c256fe8e82ce3a90b0dbaafc6581c hasDbXref "PMID:15992143" @default.
- B4a7c256fe8e82ce3a90b0dbaafc6581c type Axiom @default.
- B4a7c256fe8e82ce3a90b0dbaafc6581c annotatedProperty IAO_0000115 @default.
- B4a7c256fe8e82ce3a90b0dbaafc6581c annotatedSource SO_0000815 @default.
- B4a7c256fe8e82ce3a90b0dbaafc6581c annotatedTarget "By definition, minigenes are short open-reading frames (ORF), usually encoding approximately 9 to 20 amino acids, which are expressed in vivo (as distinct from being synthesized as peptide or protein ex vivo and subsequently injected). The in vivo synthesis confers a distinct advantage: the expressed sequences can enter both antigen presentation pathways, MHC I (inducing CD8+ T- cells, which are usually cytotoxic T-lymphocytes (CTL)) and MHC II (inducing CD4+ T-cells, usually 'T-helpers' (Th)); and can encounter B-cells, inducing antibody responses. Three main vector approaches have been used to deliver minigenes: viral vectors, bacterial vectors and plasmid DNA." @default.